NME1 Human, Active
Non-metastatic cells 1, Nucleoside diphosphate kinase A, NDP kinase A, AWD, GAAD, NB, NBS, NDPK-A, NM23, NM23-H1.
Greater than 90.0% as determined by SDS-PAGE.
Description
NME1 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 152 amino acids (1-152 a.a.) and having a molecular mass of 17.1kDa.
Product Specs
NME1, initially identified as a metastasis suppressor gene, encodes a protein found in various tumor types. Its expression levels can influence metastatic potential. Low NME1 levels are associated with aggressive carcinomas (e.g., colon, breast, gastric, melanoma), while high levels have been observed in advanced thyroid cancer.
Recombinant human NME1, produced in E. coli, is a single, non-glycosylated polypeptide chain comprising 152 amino acids (residues 1-152). It has a molecular weight of 17.1 kDa.
The NME1 solution is provided at a concentration of 1 mg/ml in a buffer containing 10% glycerol, 20 mM Tris-HCl (pH 7.5), and 1 mM DTT.
For short-term storage (up to 2-4 weeks), store at 4°C. For long-term storage, freeze at -20°C. Adding a carrier protein (0.1% HSA or BSA) is recommended for long-term storage. Avoid repeated freeze-thaw cycles.
Purity is determined to be greater than 90.0% by SDS-PAGE analysis.
The specific activity, exceeding 1,200 units/mg, is determined by measuring the enzyme's ability to convert ATP and TDP to ADP and TTP. One unit is defined as the amount of enzyme required to convert 1.0 µmol of ATP and TDP to ADP and TTP per minute at pH 7.5 and 25°C using a coupled PK/LDH assay system.
Non-metastatic cells 1, Nucleoside diphosphate kinase A, NDP kinase A, AWD, GAAD, NB, NBS, NDPK-A, NM23, NM23-H1.
MANCERTFIA IKPDGVQRGL VGEIIKRFEQ KGFRLVGLKF MQASEDLLKE HYVDLKDRPF FAGLVKYMHS GPVVAMVWEG LNVVKTGRVM LGETNPADSK PGTIRGDFCI QVGRNIIHGS DSVESAEKEI GLWFHPEELV DYTSCAQNWI YE
Product Science Overview
NME1 was first discovered due to its ability to suppress metastasis in certain cancer cells. It is involved in the regulation of cellular processes such as proliferation, differentiation, and apoptosis. The protein’s activity is linked to its role in the synthesis of nucleoside triphosphates other than ATP, which are essential for DNA and RNA synthesis .
The human recombinant form of NME1 is produced in E. coli and is a single, non-glycosylated polypeptide chain containing 152 amino acids, with a molecular mass of 17.1 kDa . The protein is typically provided as a sterile, filtered colorless solution, formulated with 10% glycerol, 20mM Tris-HCl buffer (pH 7.5), and 1mM DTT .
NME1 exhibits significant biological activity, with a specific activity greater than 1,200 units/mg. This activity is defined as the amount of enzyme that converts 1.0 µmole each of ATP and TDP to ADP and TTP per minute at pH 7.5 at 25°C in a coupled system with pyruvate kinase (PK) and lactate dehydrogenase (LDH) .
The levels of NME1 can vary significantly in different types of tumors. Low levels of NME1 are often associated with aggressive carcinomas such as colon, breast, gastric, and melanoma cancers. Conversely, high levels of NME1 have been linked to advanced thyroid cancer . This dual role makes NME1 a critical marker for understanding tumor progression and potential metastasis.
For optimal stability, NME1 should be stored at 4°C if it will be used within 2-4 weeks. For longer storage periods, it is recommended to freeze the protein at -20°C and add a carrier protein such as 0.1% human serum albumin (HSA) or bovine serum albumin (BSA) to prevent degradation. It is important to avoid multiple freeze-thaw cycles to maintain the protein’s integrity .
